Drug, alcohol and tobacco use disorders are a global burden affecting millions of people.
Despite decades of research, treatment options are sparse or missing, and relapse rates are …

One of the major challenges in preclinical studies of alcohol abuse and dependence
remains the development of paradigms that will elicit high ethanol intake and mimic the …

Growing evidence indicates that the glucagon-like peptide-1 (GLP-1) system is involved in
the neurobiology of addictive behaviors, and GLP-1 analogues may be used for the …

Background Alcohol use disorder (AUD) is a chronic, relapsing brain disorder that accounts
for 5% of deaths annually, and there is an urgent need to develop new targets for …

Background Glucagon-like peptide1 receptor (GLP-1R) agonists have been found to reduce
alcohol drinking in rodents and overweight patients with alcohol use disorder (AUD) …

Glucagon-like peptide-1 (GLP-1) is currently one of the most promising biological systems
for the development of effective obesity pharmacotherapies. Long-acting GLP-1 analogs …

Abstract Alcohol Use Disorder (AUD) contributes significantly to global mortality. GLP-1
(Glucagon-like peptide-1) and GLP-1/GIP (Glucose-dependent Insulinotropic Polypeptide) …

Converging evidence across species highlights the contribution of environmental stress to
anhedonia (loss of pleasure and/or motivation). However, despite a clear link between …

Abstract Glucagon-like peptide-1 (GLP-1) is released from endocrine L-cells lining the gut in
response to food ingestion. However, GLP-1 is also produced in the nucleus of the solitary …

Tobacco smokers titrate their nicotine intake to avoid its noxious effects, sensitivity to which
may influence vulnerability to tobacco dependence, yet mechanisms of nicotine avoidance …